Antares Pharma, Inc. (ATRS) ATRS : Summary for Antares Pharma, Inc. - Yahoo Finance Antares Pharma: Excellent Risk-Reward Profile Antares Pharma: Excellent Risk-Reward Profile - Antares Pharma Inc. (NASDAQ:ATRS) | Seeking Alpha Summary · The current share price remains well below reasonable valuation of expectations. · Article will discuss financial and milestone expectations for the remainder of 2018. · Company remains a viable acquisition candidate, especially in the likely aftermath of Xyosted being approved by the FDA. · Regardless of the direction the company takes, its profitable business model is set for fulfillment. In the aftermath of Antares Pharma (ATRS) falling from $4.09 in mid-October to $1.58 by mid-November 2017 after it was learned that the FDA had issued a CRL for the company's TRT (testosterone replacement therapy) drug Xyosted, the stock has made a slow comeback beginning in December to a current price near $2.50. Since mid-December the shares have resumed an upward trend, steadily making higher highs, retreating to higher lows. With 200-day average trading volume near 1.5 million shares per day, volume in the last 30 days has dropped to less than half at 729,000, suggesting that the market has capitulated to under-performance. However, building fundamentals support a position that the remainder of 2018 will unfold much differently than 2017. While Antares stock has remained a highly volatile investment during the time frame covered by the author, it is highly doubtful it will ever see $2.00 again. By year-end, the share price should exceed $5.00 and has the potential to trade much higher in the next 12 months.